News

Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.


Jonathan Wang Joins Burrill & Company to Focus on Greater China Opportunities

February 02, 2005

San Francisco, CA - February 02, 2005

Burrill & Company, a San Francisco based life sciences merchant bank has announced today that Dr. Jonathan Wang has joined the firm as General Manager for Greater China. Dr. Wang will build and lead Burrill’s Greater China Group (GCG), focused on strategic partnering and investing opportunities related to Greater China. He will manage a variety of Greater China-related strategic partnering opportunities, including collaborations, product and technology licensing and mergers & acquisitions.

Dr. Wang has over fifteen years of experience in the life sciences field in a variety of functions, including venture capital, finance, entrepreneurship and research. Prior to joining Burrill, Dr. Wang worked for WI Harper Group (WIH) and Walden International (WI), both of which have been ranked among the top ten foreign venture capital firms in China. At WIH, Dr. Wang was Managing Director, overseeing the firm’s life sciences activities worldwide and leading the company’s Merchant Banking Group. Prior, Dr. Wang managed life sciences investments for WI, a multi-national venture capital firm with $1.5 billion in funds. He has frequently published articles on the life sciences industry and spoken at important life sciences conferences.

Dr. Wang has obtained a Ph.D. in Molecular Neurobiology from Columbia University under the supervision of Dr. Eric Kandel, a Nobel Laureate. He also holds an M.B.A. from Stanford University.

“Greater China, with its tremendous cost advantages and a rapidly growing domestic market, is becoming an important force in the global life sciences landscape. Burrill & Company, with a vision of China becoming a critical global pharmaceutical development and manufacturing center in the near future, has established GCG to ‘bridge’ the life science industries in Greater China and the Western world. Jonathan Wang brings the skills and relationships that will fuel the success of Burrill’s GCG and our Greater China strategies," said G. Steven Burrill, CEO, Burrill & Company.

About Burrill & Company
Burrill & Company is a life sciences merchant bank, focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, human healthcare and related medical technologies, wellness and nutraceuticals, agricultural technologies, and industrial biotechnology (biomaterials/bioprocesses).

Venture Capital
The Burrill family of venture capital funds, with over $500 million under management, includes the Burrill Life Sciences Capital Fund, the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and its successor—the Burrill Agbio Capital Fund II, and the Burrill Nutraceuticals Capital Fund. Burrill & Company has commenced its Burrill Life Sciences Capital Fund III, a $300-$500 million fund, which it expects to become operational in 2005.

Merchant Banking Services
Burrill & Company assists life science companies to identify, negotiate and close strategic partnerships and merger and acquisition transactions providing access to resources, technologies or collaborations essential for executing company business plans. We have completed 20 strategic partnerships with a value in excess of $1 billion. Service lines include:

  • Strategic Partnering including licensing, research and other collaborations
  • Strategic Advisory Services including new company formation
  • Merger & Acquisitions across life sciences
  • Spin-outs ranging from products, to research divisions to disease area franchises
Biotech 2004/Burrill Datacenter
Burrill & Company’s annual analysis of the “State of the Industry” has been an important part of the biotech industry’s view of itself over the last 19 years. Biotech 2005—Life Sciences: A Move Towards Predictability, is a perspective on where the industry has been and is going will be released Q1 05. In addition, the newly created Burrill Datacenter is an online resource for keeping up-to-date information from the biotech industry at your fingertips, including updated data from Biotech 2005. To order Biotech 2005 or to subscribe to the Burrill Datacenter, visit www.burrilldatacenter.com or call (415) 591-5400.

For more information, please visit Burrill & Company's website at www.burrillandco.com.

Back to News list  
News Archive: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All